Metagenomi
Discovering the next generation of gene-editing systems for use in treating genetic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | $93.8m | IPO |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 6978 % | 160 % | 17 % | (42 %) | 17 % | (72 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (9676 %) | (228 %) | (132 %) | (142 %) | (330 %) | (343 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (8824 %) | (253 %) | (153 %) | (149 %) | (344 %) | (358 %) | (1625 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5958 % | 251 % | 211 % | 209 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Metagenomi is a biotech startup that operates in the field of genetic medicine. The company uses a unique approach to discover and develop new genome editing tools, with the ultimate goal of creating potentially curative therapeutics. Metagenomi's primary clients are likely to be healthcare providers and patients suffering from diseases that could be treated or cured through gene editing.
The company's business model revolves around the use of metagenomics, a field of study that involves analyzing genomes from organisms found in the natural environment. Metagenomi ventures into unexplored natural environments to source undiscovered genetic material, which is then brought back to their lab for sequencing and engineering into genetic medicines.
To expedite the process of discovery, Metagenomi leverages artificial intelligence (AI) and high-throughput screening. These technologies allow the company to rapidly sift through billions of novel proteins from the natural world, helping them find genome editing tools that are naturally evolved to be highly efficient, specific, and targetable.
The company's revenue is likely to come from the sale of these genetic medicines once they have been developed and approved for use. Given the potential of gene editing to cure a wide range of diseases, the market for Metagenomi's products could be substantial.
Keywords: Metagenomi, genetic medicine, genome editing tools, metagenomics, artificial intelligence, high-throughput screening, novel proteins, genetic material, therapeutic gene edit, genetic medicines.